Do genetic variants affect Wegovy and Mounjaro weight loss?

What researchers found

Scientists report genetic variants that are associated with slightly greater weight loss and with differences in the incidence of side effects among people taking the obesity drugs Wegovy and Mounjaro. The findings point to biology—beyond lifestyle alone—that can influence how patients respond to GLP-1–based therapies.

Why it matters

These results matter because GLP-1 drugs do not produce the same outcomes for everyone. Even when people are on similar doses, some lose more weight than others and some experience more adverse effects. If genetic markers can help explain that variation, clinicians may eventually be able to predict who is more likely to benefit and who might need closer monitoring.

The article frames the findings as part of a growing effort to make treatment selection more personalized.

What’s known and what isn’t

The story describes an association between specific genetic variants and outcomes, but it does not provide enough detail to say that testing will be used routinely in clinical practice. It also doesn’t specify which variants were most predictive or what clinical thresholds would trigger changes in care.

Bottom line

The research adds to evidence that genetics can help explain why weight-loss results with these medications vary. That could support more individualized approaches—especially around expectations for weight change and the likelihood of side effects—once the findings are validated for broader clinical use.